ArticlePhysiological reports2020
Muscle and serum myostatin expression in type 1 diabetes.
Article in Physiological reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Alterations in systemic and skeletal muscle myostatin regulation are most prominent at disease onset and associate with muscle-related outcomes in idiopathic inflammatory myopathies.Arthritis research & therapy · 2026Article
- Glycemic Risk Across Exercise Modalities in Adults with Type 1 Diabetes Using Continuous Glucose Monitoring and Wearable Sensors: A Prospective Cohort Study.Journal of functional morphology and kinesiology · 2026Article
- Myosteatosis in type 1 diabetes: immunometabolic mechanisms, biomarkers, and therapeutic targets.Frontiers in endocrinology · 2026Review
- Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders.Journal of bone metabolism · 2025Article
- Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions.Molecular and cellular biochemistry · 2025Review
- Apelin and Myostatin Levels in Adolescents With Type-1-Diabetes.Pediatric diabetes · 2025Article
- A myostatin inhibitory antibody combined with insulin, partially rescues the musculoskeletal phenotype of female insulin-deficient diabetic mice.Frontiers in endocrinology · 2025Article
- Roles of myokines in osteoporosis under physiological and diabetic conditions.Frontiers in endocrinology · 2025Review
- Myostatin as a plausible biomarker for early stage of sarcopenic obesity.Scientific reports · 2024Article
- The Effect of Geranylgeraniol and Ginger on Satellite Cells Myogenic State in Type 2 Diabetic Rats.Current issues in molecular biology · 2024Article
- The interplay between the muscle and liver in the regulation of glucolipid metabolism.Journal of molecular cell biology · 2024Article
- Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers.Journal of clinical medicine · 2024Review
- Article
- Myostatin: a potential therapeutic target for metabolic syndrome.Frontiers in endocrinology · 2023Review
- Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.Endocrine reviews · 2022Review
- Diabetic Bone Disease and Diabetic Myopathy: Manifestations of the Impaired Muscle-Bone Unit in Type 1 Diabetes.Journal of diabetes research · 2022Review
- Myostatin serum levels in children with type 1 diabetes mellitus.Hormones (Athens, Greece) · 2021Article
- Deciphering Myostatin's Regulatory, Metabolic, and Developmental Influence in Skeletal Diseases.Frontiers in genetics · 2021Review
- Muscle and serum myostatin expression in type 1 diabetes.Physiological reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle-wasting diseases, has not been reported in humans with T1D but has been demonstrated to be elevated in preclinical diabetes models. Thus, the purpose of this study was to determine if there is an elevated expression of myostatin in the serum and skeletal muscle of persons with T1D compared to controls. Secondarily, we aimed to explore relationships between myostatin expression and clinically important metrics (e.g., HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.